Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (11-20 of 468) with videos related to

Pageof 47
Sort By:
JAMA Oncology|February 25, 2021
Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality RatesHarpreet Singh, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Oncology Drug Development: Challenges of Increasingly Available TherapiesSundeep Agrawal, Richard Pazdur
Nature Reviews. Clinical Oncology|January 24, 2019
Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time reviewGideon M Blumenthal, Richard Pazdur
JAMA Oncology|December 23, 2020
FDA Oncology Center of Excellence During COVID-19-Working for Patients With CancerJennifer J Gao, Richard Pazdur
Nature Reviews. Clinical Oncology|January 30, 2021
Oncology approvals in 2020: a year of firsts in the midst of a pandemicLaleh Amiri-Kordestani, Richard Pazdur
The New England Journal of Medicine|November 8, 2018
Immunotherapy Combinations in Multiple Myeloma - Known UnknownsNicole J Gormley, Richard Pazdur
The New England Journal of Medicine|April 21, 2021
"Dangling" Accelerated Approvals in OncologyJulia A Beaver, Richard Pazdur
Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2009
Oncology drug review processAnn T Farrell, Richard Pazdur
Nature Reviews. Clinical Oncology|February 21, 2017
Approvals in 2016: the march of the checkpoint inhibitorsGideon M Blumenthal, Richard Pazdur
Nature Reviews. Clinical Oncology|February 1, 2018
Approvals in 2017: gene therapies and site-agnostic indicationsGideon M Blumenthal, Richard Pazdur
Pageof 47

Showing results (11-20 of 468) with videos related to

Sort By:
Pageof 47
JAMA Oncology|February 25, 2021
Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality RatesHarpreet Singh, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Oncology Drug Development: Challenges of Increasingly Available TherapiesSundeep Agrawal, Richard Pazdur
Nature Reviews. Clinical Oncology|January 24, 2019
Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time reviewGideon M Blumenthal, Richard Pazdur
JAMA Oncology|December 23, 2020
FDA Oncology Center of Excellence During COVID-19-Working for Patients With CancerJennifer J Gao, Richard Pazdur
Nature Reviews. Clinical Oncology|January 30, 2021
Oncology approvals in 2020: a year of firsts in the midst of a pandemicLaleh Amiri-Kordestani, Richard Pazdur
The New England Journal of Medicine|November 8, 2018
Immunotherapy Combinations in Multiple Myeloma - Known UnknownsNicole J Gormley, Richard Pazdur
The New England Journal of Medicine|April 21, 2021
"Dangling" Accelerated Approvals in OncologyJulia A Beaver, Richard Pazdur
Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2009
Oncology drug review processAnn T Farrell, Richard Pazdur
Nature Reviews. Clinical Oncology|February 21, 2017
Approvals in 2016: the march of the checkpoint inhibitorsGideon M Blumenthal, Richard Pazdur
Nature Reviews. Clinical Oncology|February 1, 2018
Approvals in 2017: gene therapies and site-agnostic indicationsGideon M Blumenthal, Richard Pazdur
Pageof 47